NASDAQ$PACB
Pacific Biosciences of California Inc · Q1 2026 earnings
Q1 2026 earnings · · After market close · Investor relations
Briefing
PacBio reported Q1 2026 total revenue of $37.2M and a net loss of $8.3M, narrowing from prior-year loss.
Q1 2026 total revenue was $37.2 million (flat YoY) for long-read sequencing instruments and consumables. Net loss narrowed to $8.3 million from $426.1 million, which included large one-time charges in the prior year. Operating loss continued as commercial traction builds on Revio platform.
- Total revenue $37.2M (flat YoY).
- Net loss $(8.3)M vs $(426.1)M prior year (one-time items).
- Sequencing instrument placements and consumables mix.
- Competition from short-read and other long-read platforms.
Headline financials
Revenue & EPS history
Pacific Biosciences · Revenue · Quarterly
$37.2M
Revenue by segment
Pacific Biosciences · $47.6M total across 3 segments · Q2 2023
- Instrument Revenue$24.7M+42.0%51.9%
- Consumables Revenue$17.9M+29.7%37.6%
- Service & Other Revenue$5M+150.0%10.5%
Forward guidance
Sequencing company discusses instrument installed base, consumable pull-through, and cost cuts.
Tailwinds
- Material reduction in GAAP net loss year over year.
- Stable revenue on installed base growth.
Headwinds
- Still operating at a loss.
- Capital equipment sales cyclicality in genomics.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q1 2026
+1.6%
Avg return
Earnings day
+2.4%
Avg return
5 days after
+4.1%
Avg return
30 days after
47%
29 / 62 earnings
Positive
+69.9%
Q3 2018
Best reaction
-27.2%
Q3 2017
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -14.5% | -23.0% | -12.7% | |
| Q4 2025 | -7.1% | -11.4% | -27.7% | |
| Q3 2025 | -1.1% | -2.2% | +34.3% | |
| Q1 2025 | -8.4% | -8.3% | -5.0% | |
| Q4 2024 | +25.0% | +19.6% | -17.6% | |
| Q3 2024 | -13.2% | -16.6% | -23.4% | |
| Q2 2024 | +4.4% | -10.6% | -1.2% | |
| Q1 2024 | +5.4% | +32.7% | +19.6% | |
| Q4 2023 | +9.7% | -18.6% | -41.7% | |
| Q3 2023 | +20.9% | +15.2% | +48.7% | |
| Q2 2023 | -0.7% | -3.7% | -13.3% | |
| Q1 2023 | -2.8% | -0.5% | +13.6% | |
| Q4 2022 | +5.1% | -17.6% | -25.2% | |
| Q3 2022 | +2.1% | +11.8% | +31.9% | |
| Q2 2022 | +11.4% | +27.4% | -10.3% | |
| Q1 2022 | -4.5% | +2.9% | -7.1% | |
| Q4 2021 | +8.2% | +4.5% | -0.5% | |
| Q3 2021 | +6.6% | +5.3% | -22.1% | |
| Q2 2021 | +5.5% | +4.1% | +0.2% | |
| Q1 2021 | -0.2% | -3.4% | +4.7% | |
| Q4 2020 | +29.4% | +27.3% | -14.3% | |
| Q3 2020 | +16.1% | +18.2% | +62.7% | |
| Q2 2020 | -3.1% | +1.0% | +66.5% | |
| Q1 2020 | +9.4% | +11.6% | +26.7% | |
| Q4 2019 | -4.1% | -12.3% | -16.3% | |
| Q3 2019 | -2.8% | -4.8% | +3.5% | |
| Q2 2019 | +3.5% | +5.6% | +4.1% | |
| Q1 2019 | -0.3% | -1.3% | -9.6% | |
| Q4 2018 | -1.5% | -0.8% | +1.5% | |
| Q3 2018 | +69.9% | +71.2% | +75.7% | |
| Q2 2018 | +0.5% | +4.7% | +31.7% | |
| Q1 2018 | -8.7% | -6.9% | +0.8% | |
| Q4 2017 | -4.9% | -8.5% | -16.2% | |
| Q3 2017 | -27.2% | -33.9% | -27.2% | |
| Q2 2017 | +13.7% | +38.8% | +57.1% | |
| Q1 2017 | -19.4% | -20.3% | -27.2% | |
| Q4 2016 | -1.2% | -1.7% | +6.2% | |
| Q3 2016 | -20.4% | -12.7% | -17.4% | |
| Q2 2016 | +14.6% | +10.3% | +6.8% | |
| Q1 2016 | +18.2% | — | — | |
| Q4 2015 | -24.0% | — | — | |
| Q3 2015 | +9.7% | — | — | |
| Q2 2015 | -17.2% | — | — | |
| Q1 2015 | -0.5% | — | — | |
| Q4 2014 | -16.4% | — | — | |
| Q3 2014 | +11.8% | — | — | |
| Q2 2014 | +2.6% | — | — | |
| Q1 2014 | -5.6% | — | — | |
| Q4 2013 | +2.2% | — | — | |
| Q3 2013 | +0.0% | — | — | |
| Q2 2013 | +5.7% | — | — | |
| Q1 2013 | -0.4% | — | — | |
| Q4 2012 | +0.0% | — | — | |
| Q3 2012 | -5.4% | — | — | |
| Q2 2012 | +2.9% | — | — | |
| Q1 2012 | +0.0% | — | — | |
| Q4 2011 | -12.7% | — | — | |
| Q3 2011 | -7.8% | — | — | |
| Q2 2011 | +8.9% | — | — | |
| Q1 2011 | -1.3% | — | — | |
| Q4 2010 | +2.7% | — | — | |
| Q3 2010 | +9.2% | — | — | |
| Q2 2010 | — | — | — | |
| Q1 2010 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro